Cover Image
Market Research Report

Stroke - Pipeline Review, H2 2018

Published by Global Markets Direct Product code 229744
Published Content info 544 Pages
Delivery time: 1-2 business days
Price
Back to Top
Stroke - Pipeline Review, H2 2018
Published: September 11, 2018 Content info: 544 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Stroke - Pipeline Review, H2 2018, provides an overview of the Stroke (Cardiovascular) pipeline landscape.

Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear suddenly. Initially the person may feel sick, and look pale and very unwell. They may complain of a sudden headache. They may have sudden numbness in their face or limbs, particularly down one side of their body. They may appear confused and have trouble talking or understanding what is being said to them. They may have vision problems, and trouble walking or keeping their balance.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Stroke - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Stroke (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Stroke (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Stroke and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 26, 23, 2, 104, 15 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 31 and 4 molecules, respectively.

Stroke (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Stroke (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Stroke (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Stroke (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Stroke (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Stroke (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Stroke (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Stroke (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC10762IDB

Table of Contents

  • Table of Contents
  • Introduction
  • Stroke - Overview
  • Stroke - Therapeutics Development
  • Stroke - Therapeutics Assessment
  • Stroke - Companies Involved in Therapeutics Development
  • Stroke - Drug Profiles
  • Stroke - Dormant Projects
  • Stroke - Discontinued Products
  • Stroke - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Stroke, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Stroke - Pipeline by Acorda Therapeutics Inc, H2 2018
  • Stroke - Pipeline by Acticor Biotech SAS, H2 2018
  • Stroke - Pipeline by Addex Therapeutics Ltd, H2 2018
  • Stroke - Pipeline by Affibody AB, H2 2018
  • Stroke - Pipeline by Amarantus Bioscience Holdings Inc, H2 2018
  • Stroke - Pipeline by Anavex Life Sciences Corp, H2 2018
  • Stroke - Pipeline by Antoxis Ltd, H2 2018
  • Stroke - Pipeline by Apellis Pharmaceuticals Inc, H2 2018
  • Stroke - Pipeline by AptaTargets SL, H2 2018
  • Stroke - Pipeline by ArmaGen Inc, H2 2018
  • Stroke - Pipeline by Artelo Biosciences Inc, H2 2018
  • Stroke - Pipeline by ArunA Biomedical Inc, H2 2018
  • Stroke - Pipeline by AstraZeneca Plc, H2 2018
  • Stroke - Pipeline by Athersys Inc, H2 2018
  • Stroke - Pipeline by BioAxone BioSciences Inc, H2 2018
  • Stroke - Pipeline by Biogen Inc, H2 2018
  • Stroke - Pipeline by BioTime Inc, H2 2018
  • Stroke - Pipeline by Boehringer Ingelheim GmbH, H2 2018
  • Stroke - Pipeline by Cardax Inc, H2 2018
  • Stroke - Pipeline by Celltrion Inc, H2 2018
  • Stroke - Pipeline by CHA Bio & Diostech Co Ltd, H2 2018
  • Stroke - Pipeline by CohBar Inc, H2 2018
  • Stroke - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
  • Stroke - Pipeline by DiaMedica Therapeutics Inc, H2 2018
  • Stroke - Pipeline by Diffusion Pharmaceuticals Inc, H2 2018
  • Stroke - Pipeline by Epigen Biosciences Inc, H2 2018
  • Stroke - Pipeline by Evgen Pharma Plc, H2 2018
  • Stroke - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
  • Stroke - Pipeline by Fina Biotech SL, H2 2018
  • Stroke - Pipeline by Freeox Biotech SL, H2 2018
  • Stroke - Pipeline by GC Pharma, H2 2018
  • Stroke - Pipeline by Genervon Biopharmaceuticals LLC, H2 2018
  • Stroke - Pipeline by Glialogix Inc, H2 2018
  • Stroke - Pipeline by Glucox Biotech AB, H2 2018
  • Stroke - Pipeline by Immunwork Inc, H2 2018
  • Stroke - Pipeline by Instituto Biomar SA, H2 2018
  • Stroke - Pipeline by International Stem Cell Corp, H2 2018
  • Stroke - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2018
  • Stroke - Pipeline by JT Pharmaceuticals Inc, H2 2018
  • Stroke - Pipeline by Les Laboratoires Servier SAS, H2 2018
  • Stroke - Pipeline by Living Cell Technologies Ltd, H2 2018
  • Stroke - Pipeline by Lixte Biotechnology Holdings Inc, H2 2018
  • Stroke - Pipeline by Lumosa Therapeutics Co Ltd, H2 2018
  • Stroke - Pipeline by M et P Pharma AG, H2 2018
  • Stroke - Pipeline by Mapreg SAS, H2 2018
  • Stroke - Pipeline by Meridigen Biotech Co Ltd, H2 2018
  • Stroke - Pipeline by Neuralstem Inc, H2 2018
  • Stroke - Pipeline by Neuren Pharmaceuticals Ltd, H2 2018
  • Stroke - Pipeline by Neurofx Inc, H2 2018
  • Stroke - Pipeline by NeuroNascent Inc, H2 2018
  • Stroke - Pipeline by NeurOp Inc, H2 2018
  • Stroke - Pipeline by New World Laboratories Inc, H2 2018
  • Stroke - Pipeline by Nipro Corp, H2 2018
  • Stroke - Pipeline by NoNO Inc, H2 2018

List of Figures

  • Number of Products under Development for Stroke, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Top 10 Routes of Administration, H2 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018
Back to Top